<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01244100</url>
  </required_header>
  <id_info>
    <org_study_id>PL-ASA-003</org_study_id>
    <nct_id>NCT01244100</nct_id>
  </id_info>
  <brief_title>Food-Effect Pharmacokinetic Study of PL2200</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>PLx Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PLx Pharma</source>
  <brief_summary>
    <textblock>
      This trial is a food-effect study to assess fasted versus fed pharmacokinetics of PL2200.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of food by ratio of least-squares means (LSM) of the pharmacokinetic (PK) parameter of AUC0-t of the primary metabolite, salicylic acid, in the fed state versus the fasted state.</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of food by ratio of least-squares means (LSM) of the PK parameter of AUC0-inf of the primary metabolite, salicylic acid, in the fed state versus the fasted state.</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of food by ratio of least-squares means (LSM) of the PK parameter of Cmax of the primary metabolite, salicylic acid, in the fed state versus the fasted state.</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PL2200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PL2200 fasted</intervention_name>
    <description>Fasted state</description>
    <arm_group_label>PL2200</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PL2200 fed</intervention_name>
    <description>Fed state</description>
    <arm_group_label>PL2200</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy normal male and female volunteers between 21 and 65 years of age.

        Exclusion Criteria:

          -  Abnormal findings on physical examination or clinical laboratories, or significant
             medical history.

          -  Subject with hypersensitivity or contraindications to aspirin, ibuprofen, or other
             nonsteroidal anti-inflammatory drug (NSAID).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Upendra K Marathi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>PLx Pharma Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Houston Institute for Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2010</study_first_submitted>
  <study_first_submitted_qc>November 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2010</study_first_posted>
  <last_update_submitted>December 10, 2010</last_update_submitted>
  <last_update_submitted_qc>December 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jason Moore, Vice President</name_title>
    <organization>PLx Pharma Inc.</organization>
  </responsible_party>
  <keyword>Food-effects PK study in healthy subjects.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

